These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 38195783

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A comparative study of the use of bioactive glass S53P4 and antibiotic-loaded calcium-based bone substitutes in the treatment of chronic osteomyelitis: a retrospective comparative study.
    Romanò CL, Logoluso N, Meani E, Romanò D, De Vecchi E, Vassena C, Drago L.
    Bone Joint J; 2014 Jun; 96-B(6):845-50. PubMed ID: 24891588
    [Abstract] [Full Text] [Related]

  • 5. Treatment of infected tibial non-unions using a BMAC and S53P4 BAG combination for reconstruction of segmental bone defects: A clinical case series.
    Van Vugt TAG, Geurts JAP, Blokhuis TJ.
    Injury; 2021 Jun; 52 Suppl 2():S67-S71. PubMed ID: 33039177
    [Abstract] [Full Text] [Related]

  • 6. Utilisation of bioactive glass S53P4 inside an induced membrane for severe bone defect with high risk of infection: a multi-center preliminary experience.
    Aurégan JC, Villain B, Glombitza M, Blokhuis T, Heinänen M, Bégué T.
    Injury; 2022 Oct; 53 Suppl 2():S13-S19. PubMed ID: 35871084
    [Abstract] [Full Text] [Related]

  • 7. Bioactive glass S53P4 as bone graft substitute in treatment of osteomyelitis.
    Lindfors NC, Hyvönen P, Nyyssönen M, Kirjavainen M, Kankare J, Gullichsen E, Salo J.
    Bone; 2010 Aug; 47(2):212-8. PubMed ID: 20624692
    [Abstract] [Full Text] [Related]

  • 8. Bioactive glass as dead space management following debridement of type 3 chronic osteomyelitis.
    Oosthuysen W, Venter R, Tanwar Y, Ferreira N.
    Int Orthop; 2020 Mar; 44(3):421-428. PubMed ID: 31701158
    [Abstract] [Full Text] [Related]

  • 9. Antibacterial Bioactive Glass, S53P4, for Chronic Bone Infections - A Multinational Study.
    Lindfors N, Geurts J, Drago L, Arts JJ, Juutilainen V, Hyvönen P, Suda AJ, Domenico A, Artiaco S, Alizadeh C, Brychcy A, Bialecki J, Romanò CL.
    Adv Exp Med Biol; 2017 Mar; 971():81-92. PubMed ID: 28050878
    [Abstract] [Full Text] [Related]

  • 10. Bioactive glass BAG-S53P4 for the adjunctive treatment of chronic osteomyelitis of the long bones: an in vitro and prospective clinical study.
    Drago L, Romanò D, De Vecchi E, Vassena C, Logoluso N, Mattina R, Romanò CL.
    BMC Infect Dis; 2013 Dec 10; 13():584. PubMed ID: 24325278
    [Abstract] [Full Text] [Related]

  • 11. In vitro antibacterial activity of bioactive glass S53P4 on multiresistant pathogens causing osteomyelitis and prosthetic joint infection.
    Cunha MT, Murça MA, Nigro S, Klautau GB, Salles MJC.
    BMC Infect Dis; 2018 Apr 03; 18(1):157. PubMed ID: 29614973
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of antibacterial bioactive glass S53P4 against S. aureus biofilms grown on titanium discs in vitro.
    Coraça-Huber DC, Fille M, Hausdorfer J, Putzer D, Nogler M.
    J Orthop Res; 2014 Jan 03; 32(1):175-7. PubMed ID: 24108602
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Clinical applications of Bioactive glass S53P4 in bone infections: a systematic review.
    Bigoni M, Turati M, Zanchi N, Lombardo AS, Graci J, Omeljaniuk RJ, Zatti G, Gaddi D.
    Eur Rev Med Pharmacol Sci; 2019 Apr 03; 23(2 Suppl):240-251. PubMed ID: 30977891
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and Safety of Bioactive Glass S53P4 as a Treatment for Diabetic Foot Osteomyelitis.
    De Giglio R, Di Vieste G, Mondello T, Balduzzi G, Masserini B, Formenti I, Lodigiani S, Pallavicini D, Pintaudi B, Mazzone A.
    J Foot Ankle Surg; 2021 Apr 03; 60(2):292-296. PubMed ID: 33358382
    [Abstract] [Full Text] [Related]

  • 17. A RETROSPECTIVE CASE-SERIES ON THE USE OF S53P4 BIOACTIVE GLASS FOR THE ADJUNCTIVE TREATMENT OF SEPTIC DIAPHYSEAL NON-UNION.
    Gaiarsa GP, Dos Reis PR, Kojima KE, Silva JS, Lima ALLM.
    Acta Ortop Bras; 2019 Apr 03; 27(5):273-275. PubMed ID: 31839738
    [No Abstract] [Full Text] [Related]

  • 18. Bioactive glass, a new tool for the treatment in the diabetic foot recalcitrant osteomyelitis: A case series with 24-month follow-up.
    Rodríguez Á, Parra G, Cuervas-Mons M.
    Foot (Edinb); 2021 Sep 03; 48():101831. PubMed ID: 34390944
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of the clinical effectiveness of bioactive glass (S53P4) in the treatment of non-unions of the tibia and femur: study protocol of a randomized controlled non-inferiority trial.
    Tanner MC, Heller R, Westhauser F, Miska M, Ferbert T, Fischer C, Gantz S, Schmidmaier G, Haubruck P.
    Trials; 2018 May 30; 19(1):299. PubMed ID: 29843766
    [Abstract] [Full Text] [Related]

  • 20. S53P4 BIOACTIVE GLASS PUTTY IN THE LOCAL TREATMENT OF CAVITARY CHRONIC OSTEOMYELITIS.
    Reis GNBD, Cuba GT, Targa WHC, Miras PSC, Bongiovanni JC, Salles MJ, Reis FBD, Dell'aquila AM.
    Acta Ortop Bras; 2023 May 30; 31(1):e258453. PubMed ID: 36844131
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.